Anti-Human CD14 (Clone CPTC-CD14-1) – Purified No Carrier Protein

FPAIQNLALR

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0121A-3A10-H2/K3 activity is directed against human CD14 peptide sequence FPAIQNLALR.

CPTC-CD14-1

CD14 is a transmembrane glycoprotein co-receptor for toll-like receptors (TLRs) that functions in the activation of innate immune responses to viral and bacterial pathogens as well as the inflammatory response to tissue injury¹. During infection, CD14 binds pathogen-associated molecular pattern (PAMP) ligands, promotes macrophage activation by binding bacterial lipopolysaccharides or oxidized lipids, and initiates signaling cascades that activate the innate immune system. Additionally, soluble CD14 enables epithelial and endothelial cells to respond to lipopolysaccharides found on the outer membrane of gram-negative bacteria.

CD14 can also bind oxidized lipids with damage-associated molecular patterns (DAMPs) to promote the inflammatory response during injury, autoimmune disorders, and atherosclerosis¹. However, elevated CD14 has been implicated in the severity of a variety of infections, disorders, and malignancies. CD14 is elevated in response to sepsis and acute infections such as tuberculosis, influenza, HIV, and Covid-19, with higher levels corresponding to increased severity. Elevated CD14 is also associated with higher cholesterol and risk of myocardial infarction. Additionally, CD14 promotes certain autoimmune diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus) and has been implicated in increased tumor invasiveness and aggression. CD14 blockade has been proposed as a strategy to control inflammation.

EB0121A-3A10-H2/K3 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from human CD14, FPAIQNLALR². EB0121A-3A10-H2/K3 detects CD14 in whole cell lysates of HeLa, Jurkat, A549, MCF7, and H226 cell lines but does not detect recombinant protein³. EB0121A-3A10-H2/K3 does not detect CD14 by immunohistochemistry, immunofluorescence, or reverse phase protein array.

https://antibodies.cancer.gov/detail/CPTC-CD14-1#CPTC-CD14-1

CD14 is expressed on macrophages, monocytes, neutrophils, dendritic cells, T cells, B cells, liver resident Kupffer cells, enterocytes, hepatocytes, and pancreatic islet beta cells. A soluble CD14 isoform can also be released.

Toll-like receptors (TLRs), electronegative LDLPAMPs: lipopolysaccharide, CpG-DNA, Peptidoglycan, Byglican, Lipoteichoic Acid, pLpC-dsRNADAMPs: oxPAPC, S100A9, mtDNA, HSPs, Fibronectin, Beta-Amyloid

1 Sharygin D, Koniaris LG, Wells C, et al. Immunology. 169(3):260-270. 2023.
2 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
3 https://antibodies.cancer.gov/detail/CPTC-CD14-1